Addex Therapeutics Ltd (NASDAQ:ADXN) Q3 2024 Earnings Conference Call November 22, 2024 10:00 AM ET

Company Participants

Tim Dyer - Co-Founder, Board Director and Chief Executive Officer
Mikhail Kalinichev - Head, Translational Science

Conference Call Participants

Operator

Good day, and thank you for standing by. Welcome to the Addex Therapeutics Third Quarter 2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. After the speakers' presentation, there will be the question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.

I would now like to hand over the conference to our first speaker today, Tim Dyer. Please go ahead.

Tim Dyer

Thank you. Hello everyone. I would like to thank you all for attending our third quarter 2024 financial results conference call. I'm here with Mikhail Kalinichev, our Head of Translational Science, who will provide an update on our R&D programs.

I draw your attention to the press release and the financial statements issued earlier today, which are available on our website. I also draw your attention to our disclaimers. We will be making certain forward-looking statements that are based on the knowledge we have today.

I will start this conference call by giving a quick overview of our recent activities and achievements before reviewing our pipeline. I will then hand over to Misha, who will review in more detail our GABAB PAM preclinical program. I will then review our third quarter 2024 financial results. Following that, we will open the call for questions.

So we have made excellent progress in our GABAB positive allosteric modulator program with the completion of the R&D phase delivering multiple drug candidates. Our partner, Indivior, has selected a compound for development in substance use disorder and has started R&D enabling studies. Under the terms of the agreement, Addex is